Foundation Medicine Signs Data Partnership With Cota, Inc

Foundation Medicine, Inc.

and COTA, Inc. today announced an agreement to capture and analyze comprehensive genomic, clinical outcome, and cost data from patients who have undergone testing with FoundationOne^®. The resulting dataset is designed to provide health care providers and payers with the supporting clinical outcomes and costs evidence that inform value-based reimbursement decisions and cancer treatment. “Eliminating inefficiencies and improving patient care requires actionable insights supported by complete, integrated data,” said Eric Schultz, CEO of COTA. “This unprecedented collaboration with Foundation Medicine incorporates the most comprehensive genomic profiling data with COTA's unique real-world, longitudinal clinical outcomes and cost of care data to provide insights that enable both physicians and payers to move toward value-based treatment and reimbursement practices.” The collaboration will first capture clinical outcomes for patients with Stage IV non-small cell lung cancer (NSCLC), the leading cancer killer of men and women in this country, who have undergone testing with FoundationOne. The resulting longitudinal data will aim to further demonstrate the clinical utility of comprehensive genomic profiling for patients with Stage IV NSCLC and to inform potential value-based reimbursement decisions from payers. The combination of genomic data, clinical information, outcomes data and economic data will provide critical insights for both payers and physicians to fully endorse the clinical and economic benefits associated with the application of comprehensive genomic profiling in this disease setting. “The capture of clinical outcomes resulting from treatment selection informed by our comprehensive genomic profiles is essential to demonstrating the clinical and economic value of FoundationOne and to expanding utilization and access for these tests,” said Michael Pellini, CEO of Foundation Medicine. “We are pleased to work in partnership with COTA on this initiative to provide additional clarity of the impact on patient outcomes and cost of care that result from our comprehensive genomic profiling tests. We look forward to enhancing our robust collection of evidence with this integrated data package to support broader payer coverage and value-based reimbursement for our tests.” Initially, Foundation Medicine and COTA will identify patients who are newly diagnosed with Stage IV NSCLC and are enrolled in a health plan that has agreed to participate in this phase of the collaboration. Subsequent phases of the collaboration, which are currently under discussion, may include integration across the remainder of the clinical scenarios included in the appropriate use of FoundationOne and FoundationOne Heme.